Novel Oral Antiplatelet Agents

Login or register to view PDF.
Abstract

One of the mainstays of the treatment of acute coronary syndromes is the interference of thrombus formation. Over the past few years, much research has been dedicated to understanding the cellular mechanisms involved in the development of thrombus. This research has resulted in the identification of new pharmacologic targets for drug advancement as well as the development of more sophisticated versions of previously existing medications. In this article, we review the literature on the newest advances in oral antiplatelet therapies.

Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Robert P Giugliano, MD, SM, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E: rgiugliano@partners.org
Received date
27 June 2011
Accepted date
18 August 2011
Citation
US Cardiology - Volume 8 Issue 2;2011:8(2):133-140
Correspondence
Robert P Giugliano, MD, SM, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E: rgiugliano@partners.org
References
  1. Roger VL, Go AL, Lloyd-Jones DM, et al., Heart Disease and Stroke Statistics – 2011 update, Circulation, 2011;123:e18–e209.
    Crossref | PubMed
  2. Davi G, Patrono C, Platelet activation and atherothrombosis, N Engl J Med, 2007;357(24):2482–94.
    Crossref | PubMed
  3. Kulkarni S, Dopheide SM, Yap CL, et al., A revised model of platelet aggregation, J Clin Invest, 2000;105(6):783–91.
    Crossref | PubMed
  4. Covic L, Gresser AL, Kuliopulos A, Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets, Biochemistry, 2000;39:5458–67.
    Crossref | PubMed
  5. Meadows TA, Bhatt DL, Clinical aspects of platelet inhibitors and thrombus formation, Circ Res, 2007;100:1261–75.
    Crossref | PubMed
  6. Yusuf S, Zhao F, Mehta SR, et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 2001;345(7):494–502.
    Crossref | PubMed
  7. Bhatt DL, Flather MD, Hacke W, et al., Patients with prior myocardial infarction, stroke or symptomatic peripheral arterial disease in the CHARISMA trial, J Am Coll Cardiol, 2007;49(19):1982–8.
    Crossref | PubMed
  8. CAPRIE steering committee, A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 1996;348(9038):1329–39.
    Crossref | PubMed
  9. Mehta SR, Yusuf S, Peters RJ, et al., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, 2001;358:527–33.
    Crossref | PubMed
  10. Sabatine MS, Cannon CP, Gibson CM, et al., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 2005;352:1179–89.
    Crossref | PubMed
  11. Chen ZM, Jiang LX, Chen YP, et al., Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial, Lancet, 2005;366:1607–21.
    Crossref | PubMed
  12. Betrand ME, Rupprecht HJ, Urban P, et al., Double-blind study of the safety clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS), Circulation, 2000;102:624–9.
    Crossref | PubMed
  13. Savcic M, Hauert J, Bachmann F, et al., Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects, Semin Thromb Hemost, 1999;25(Suppl. 2):15–9.
    PubMed
  14. Steinhubl SR, Berger PB, Brennan DM, et al., Optimal timing for the initiation of pre-treatment with 300mg clopidogrel before percutaneous coronary intervention, J Am Coll Cardiol, 2006;47:939–43.
    Crossref | PubMed
  15. Montalescot G, Sideris G, Meuleman C, et al., A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial, J Am Coll Cardiol, 2006;48:1339–45.
    Crossref | PubMed
  16. Mehta SR, Bassand JP, Chrolavicius S, et al., Design and rationale of CURRENT-OASIS 7: A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST elevation acute coronary syndromes managed with an early invasive strategy, Am Heart J, 2008;156:1080–8.
    Crossref | PubMed
  17. Mehta SR, Bassand JP, Chrolavicius S, et al., Dose comparisons of clopidogrel and aspirin in acute coronary syndromes, N Engl J Med, 2010;363:930–42.
    Crossref | PubMed
  18. Mehta SR, Tanguay J-F, Eikelboom JW, et al., Double-dose versus standard dose clopidogrel and high-dose versus lowdose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial, Lancet, 2010;376:1233–43.
    Crossref | PubMed
  19. Mega JL, Close SL, Wiviott SD, et al., Cytochrome P-450 polymorphisms and response to clopidogrel, N Engl J Med, 2009;360(4):354–62.
    Crossref | PubMed
  20. Mega JL, Simon T, Collet JP, et al., Adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis, JAMA, 2010;304:1821–30.
    Crossref | PubMed
  21. Harmsze AM, van Werkhum JW, Ten Berg JM, et al., CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study, Eur Heart J, 2010;24:3046–53.
    Crossref | PubMed
  22. Ho PM, Maddoz TM, Wang L, et al., Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 2009;301(9):937–44.
    Crossref | PubMed
  23. Gilard M, Arnaud B, Fornily JC, et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study, J Am Coll Cardiol, 2008;51:256–60.
    Crossref | PubMed
  24. O’Donoghue ML, Braunwald E, Antman EM, et al., Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials, Lancet, 2009;374(9694):989–97.
    Crossref | PubMed
  25. Bhatt DL, Cryer BL, Contant CF, et al., Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med, 2010;363:1909–17.
    Crossref | PubMed
  26. Niitsu Y, Jakubowski JA, Sugidachi A, et al., Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity, Semin Thromb Hemost, 2005;31:184–94.
    Crossref | PubMed
  27. Wallentin L, Varenhrost C, James S, et al., Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease, Eur Heart J, 2008;29(1):21–30.
    Crossref
  28. Payne CD, Li YG, Small DS, et al., Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel, J Cardiovasc Pharmacol, 2007;50(5):555–62.
    Crossref | PubMed
  29. Gurbel PA, Bliden KP, Butler K, et al., Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study, Circulation, 2009;120:2577–85.
    Crossref | PubMed
  30. Wiviott SD, Trenk D, Frelinger AL, et al., Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutanoeus coronary intervention. The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation – thrombolysis in myocardial infarction 44 trial, Circulation, 2007;116:2923–32.
    Crossref | PubMed
  31. Wiviott SD, Braunwald E, McCabe CH, et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 2007;357(20):2001–15.
    Crossref | PubMed
  32. O’Donoghue M, Antman EM, Braunwald E, et al., The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention. A TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – thrombolysis in myocardial infarction 38) analysis, J Am Coll Cardiol, 2009;54:678–85.
    Crossref | PubMed
  33. Wiviott SD, Braunwald E, Angiolillo DJ, et al., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in myocardial infarction 38, Circulation, 2008;118:1626–36.
    Crossref | PubMed
  34. Wiviott SD, Braunwald E, McCabe CH, et al., Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial, Lancet, 2008;371(9621):1353–63.
    Crossref | PubMed
  35. Pride YB, Wiviott SD, Buros JL, et al., Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (TRITON) – Thrombolysis in myocardial infarction (TIMI) 38 substudy, Am Heart J, 2009;158:e21–e26.
    Crossref | PubMed
  36. Jernberg T, Payne CD, Winters KJ, et al., Prasugrel achieves greater inhibition of platelet aggregation and lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease, Eur Heart J, 2006;27:1166–73.
    Crossref | PubMed
  37. Storey RF, Husted S, Harrington RA, et al., Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndrome, J Am Coll Cardiol, 2007;50:1852–6.
    Crossref | PubMed
  38. Cannon CP, Husted S, Harrington RA, et al., Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial, J Am Coll Cardiol, 2007;50(19):1844–51.
    Crossref | PubMed
  39. Wallentin L, Becker RC, Budaj A, et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 2009;361:1045–57.
    Crossref | PubMed
  40. Cannon CP, Harrington RA, James S, et al., Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study, Lancet, 2010;375:283–93.
    Crossref | PubMed
  41. Prevention of cardiovascular events (e.g., death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin (PEGASUS). Available at: http://clinicaltrials.gov/ct2/show/NCT0122556 (accessed May 13, 2011).
  42. Gurbel PA, Bliden KP, Butler K, et al., Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study, Circulation, 2010;121(10):1169–71.
  43. Coughlin SR, Protease-activated receptors and platelet function, Thromb Haemost, 1999;82(2):353–6.
    PubMed
  44. Coughlin SR, Thrombin signaling and protease-activated receptors, Nature, 2000;407(6801):258–64.
    Crossref | PubMed
  45. Chackalamannil S, Wang Y, Greenlee WJ, et al., Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity, J Med Chem, 2008;51(11):3061–4.
    Crossref | PubMed
  46. Becker RC, Moliterno DJ, Jennings LK, et al., Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study, Lancet, 2009;373:919–28.
    Crossref | PubMed
  47. Morrow DA, Scirica BM, Fox KA, et al., Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2oP)-TIMI 50 trial, Am Heart J, 2009;158:335–41.
    Crossref | PubMed
  48. TRA*CER Executive and Steering Committees, The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale, Am Heart J, 2009;158(3):327–34.
    Crossref | PubMed
  49. Serebruany VL, Kogushi M, Dastros-Pitei D, et al., The invitro effects of E555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease, Thromb Haemost, 2009;102:111–9.
    Crossref | PubMed
  50. O’Donoghue ML, Bhatt DL, Wiviott SD, et al., Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trials, Circulation, 2011;123:1843–53.
    Crossref | PubMed
  51. Wiviott SD, Flather MD, O’Donoghue ML, et al., Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trials, Circulation, 2011;123:1854–63.
    Crossref | PubMed